Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

泊沙康唑 医学 伏立康唑 指南 重症监护医学 支气管肺泡灌洗 曲菌病 内科学 卡斯波芬金 病理 皮肤病科 免疫学 抗真菌
作者
Andrew J. Ullmann,José María Aguado,Sevtap Arıkan-Akdağlı,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass‐Flörl,Russell E. Lewis,Patricia Muñóz,Paul E. Verweij,Adilia Warris,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary A. Barnes,Catherine Beigelman‐Aubry,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt
出处
期刊:Clinical Microbiology and Infection [Elsevier BV]
卷期号:24: e1-e38 被引量:1271
标识
DOI:10.1016/j.cmi.2018.01.002
摘要

The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hyl-tcm完成签到 ,获得积分10
刚刚
万豪发布了新的文献求助10
刚刚
刚刚
FengYulong发布了新的文献求助30
3秒前
今后应助kekkekh欧克采纳,获得10
4秒前
李健应助动人的科研采纳,获得10
4秒前
苏素肃完成签到,获得积分10
5秒前
6秒前
6秒前
7秒前
丘比特应助认真的山兰采纳,获得10
7秒前
核桃发布了新的文献求助10
9秒前
你看起来很好吃完成签到,获得积分10
10秒前
11秒前
幸福大白发布了新的文献求助10
11秒前
12秒前
JUdy发布了新的文献求助10
12秒前
wanhe发布了新的文献求助10
12秒前
12秒前
14秒前
FengYulong完成签到,获得积分20
16秒前
洞悉完成签到,获得积分10
18秒前
18秒前
18秒前
Dr发布了新的文献求助10
18秒前
Lees应助dadada采纳,获得10
19秒前
孙鑫发布了新的文献求助10
19秒前
19秒前
核桃发布了新的文献求助10
20秒前
朱莹莹发布了新的文献求助10
20秒前
20秒前
20秒前
Billy应助周雨洁采纳,获得30
22秒前
科研通AI6应助Dr采纳,获得10
23秒前
23秒前
SJ发布了新的文献求助10
24秒前
24秒前
d6503发布了新的文献求助20
24秒前
芒果完成签到,获得积分10
24秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Pediatric Injectable Drugs 500
Instant Bonding Epoxy Technology 500
Methodology for the Human Sciences 500
ASHP Injectable Drug Information 2025 Edition 400
DEALKOXYLATION OF β-CYANOPROPIONALDEYHDE DIMETHYL ACETAL 400
Assessment of adverse effects of Alzheimer's disease medications: Analysis of notifications to Regional Pharmacovigilance Centers in Northwest France 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4373183
求助须知:如何正确求助?哪些是违规求助? 3870273
关于积分的说明 12064335
捐赠科研通 3512890
什么是DOI,文献DOI怎么找? 1927754
邀请新用户注册赠送积分活动 969624
科研通“疑难数据库(出版商)”最低求助积分说明 868461